deltatrials
Completed PHASE3 NCT00120523

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis

Sponsor: MEDA Pharma GmbH & Co. KG

Conditions Atopic Dermatitis
Interventions Pimecrolimus Topical corticosteroids
Updated 9 times since 2017 Last updated: Feb 4, 2022 Started: Apr 30, 2004 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

A PHASE3 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by MEDA Pharma GmbH & Co. KG and has accumulated 9 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Mar 2022 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MEDA Pharma GmbH & Co. KG
Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beaverton, United States, Bellflower, United States, Bridgeton, United States, Charleston, United States, Cincinnati, United States, Detroit, United States, Duluth, United States, Greenville, United States, Gresham, United States, Houston, United States and 19 more location s